Filing Flows

Filing Flows › Zenas BioPharma (ZBIO) › Next earnings date

Zenas BioPharma (ZBIO) earnings: beat the estimate

Zenas BioPharma (ZBIO) reported on Nov 5, 2026 and beat the EPS estimate: −$1.23 against −$1.27 (+3.1%). Revenue was $10.0M for Q3 2026. It beat the EPS estimate in 40% of the quarters on record.

Last result+3.1% vs estimate
Beat rate40%

The last report

Zenas BioPharma reported revenue of $10.0M for the third quarter 2026, net loss $109M. How it makes money → · Every quarter →

Zenas BioPharma: EPS against the estimate, last 5 reportsZenas BioPharma: EPS against the estimate, last 5 reportsEstimateReported−$0.85−$1.22Nov 25−$1.19−$1.39Mar 26−$1.54−$1.46May 26−$0.76−$1.77Aug 26−$1.27−$1.23Nov 26
Latest (Nov 26): Estimate −$1.27, Reported −$1.23.

Zenas BioPharma's latest quarter

Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Zenas BioPharma beat earnings?

Zenas BioPharma (ZBIO) reported on Nov 5, 2026 and beat the EPS estimate: −$1.23 against −$1.27 (+3.1%).

When does ZBIO report earnings?

The next date is not set yet.

Does Zenas BioPharma usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.